The Ramipril Efficacy In Nephropathy trial that examined the effects of ramipril on 331 patients with CKD showed that serum phosphate levels were an independent risk factor associated with CKD progression against the renotropic effect of angiotensin-converting enzyme inhibitors [13]. The gene discussed is ACE; the disease is kidney disorder.